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Helicobacter pylori (Hp) is responsible for one of the most common infections in the world. 'e prevalence exceeds 50% of the
population in developing countries, and approximately one-third of the adults are colonized in North Europe and North America.
It is considered amajor pathogenic agent of chronic gastritis, peptic ulcer, atrophic gastritis, gastric cancer, andmucosa-associated
lymphoid tissue lymphoma (MALT). Hp colonization modifies the composition of gastric microbiota that could drive the
development of gastric disorders. Currently, an emerging problem in Hp treatment is represented by the increasing rate of
antimicrobial therapy resistance. In this context, the search for adjuvant agents can be very useful to overcome this issue and
probiotics administration can represent a valid option. 'e aim of this review is to describe the gastric microbiota changes during
Hp colonization, the mechanisms of action, and a possible role of probiotics in the treatment of this infection.
1. Introduction
Helicobacter pylori (Hp) is a Gram-negative, spiral-shaped,
flagellated bacterium belonging to Proteobacteria phylum
with a strong capacity of surviving in the harsh acid milieu of
the stomach. Hp is responsible for one of the most wide-
spread infections in the world [1, 2], and the number of
infected subjects is still very high worldwide. 'e prevalence
exceeds 50% of the population in some areas of the world,
like South and East Europe, South America, and Asia. Low
socioeconomic status, bad level of education, and poor
hygienic conditions are the major related risk factors. No-
tably, about one-third of the adults are colonized in North
Europe and North America [3].
Several recent evidence have highlighted that Hp can
modify the composition of gastric microbiota and the
resulting changes can play a role in the development of Hp-
related diseases. Still, the interaction between the host,
microbiota, and Hp in the pathogenesis of these conditions
has to be fully elucidated [4].
Hp colonization can cause chronic gastritis, peptic ulcer,
atrophic gastritis, gastric adenocarcinoma, and mucosa-
associated lymphoid tissue lymphoma (MALT) [5, 6]. Hp
gastritis is considered an infectious disease regardless of
symptoms and disease stage, and eradication therapy is
strongly recommended [7]. However, a rapid emergence of
antibiotic-resistant bacteria is becoming one of the world’s
most critical public health problems, and thus, the choice of
therapeutic options for the treatment of Hp infection faces
this dilemma [8].
In this context, the use of probiotics, defined as “live
microorganisms which when administrated in adequate
amounts confer a health benefit on the host” [9] can be
helpful for their antibacterial activity against Hp and for the
interaction with the complex ecosystem of the host [10].
'e beneficial properties of probiotics on the host mi-
crobiological environment can be associated with their
potential effects on digestive microflora and gut immune
system that include their ability to compete with gut
pathogens, to increase IgA secretion, to modulate cytokine
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mRNA expression and secretion, to stimulate mucin, bac-
teriocin, and lactic acid production, and to modulate
microbiota growth [11–13].
'e aim of this review is to provide an overview of the
changes in gastric microbiota composition during Hp in-
fection and then to assess the potential role of probiotics in
Hp-induced dysbiosis and eradication. A critical appraisal of
the clinical research evidence on the data regarding Hp and
gastric microbiota composition and on the probiotics ef-
fectiveness to treatHp infection and to prevent antimicrobial
therapy side effects was made. 'e search was limited to full
manuscripts in English language.
2.Helicobacter pylori and Gastric
Microbiota Composition
'e stomach has always been considered a sterile organ. It is
not surprising that for long, it was believed that low pH of
the gastric lumen and peristalsis contributed to create an
adverse environment for bacterial survival and stable mi-
crobial colonization of this organ. However, in 1983, the
discovery of Hp by Marshall and Warren [14] gave the input
to a period of progressive discoveries in the field of gastric
infection and ensured a breakthrough in understanding
gastric microecological environment. 'e improvement in
microbial detection techniques has been crucial. 'e initial
analysis was performed using culture-based methods, which
harbor various limitations; in particular, they regard a large
amount of bacteria that are still considered “unculturable”
due to growth resistance in conventional culturemedia, need
for particular environment conditions, low bacterial growth
rate, and interaction with other bacteria or their secreted
substrates [15]. Taken together or individually, these factors
can determine an incomplete and limited representation of
the complex gastric bacterial community improperly
showing a similar gastric microbiota composition in Hp
patients compared with healthy subjects [16, 17]. Con-
versely, the most recent molecular techniques which allow
an in-depth study of the gastric microbiota have highlighted
a significant difference in microbiota composition between
Hp-positive and healthy subjects. 'e technique consists in
sequencing the ribosomal gene 16S rRNA that contains 9
variable regions, which are present in all bacteria and are
similar in the microorganisms of the same phyla. Techni-
cally, this type of analysis allows the recognition of different
bacterial species through the analysis of the genoma, which
makes it difficult to evaluate the vitality of microorganisms.
To avoid this drawback, it is preferable to use bacterial RNA
instead of DNA [18].
Currently, we know that, in healthy subjects, gastric
microbiota is composed mainly of Firmicutes, Bacteroidetes,
Proteobacteria, and Actinobacteria at phyla level. 'e most
present genera are Streptococcus, followed by Veillonella,
Prevotella, Fusobacterium, and Rothia [17, 19]. 'e analysis
performed on gastric juice and biopsies has suggested that
the density of gastric microbiota is lower than in other
parts of the gastrointestinal (GI) tract, counting about
101–103 CFU/ml [20].
'e presence of bacteria in the stomach is possible due to
the progressive shift of pH from the gastric lumen (pH 1-2)
to the mucosal surface (pH 6-7) coated with mucus which is
actively secreted by gastric glands. 'is pH gradient permits
the development of different environments that allow the
growth of microorganisms, being the mucosal surface the
more hospitable gastric area [21]. Hp colonization of gastric
mucosa alters this gastric habitat by deconstructing the
mucous layer and by alkalinization of gastric juice [22].
In Hp-positive subjects, molecular analysis showed an
overall decrease in bacterial diversity with the absolute
prevalence at phyla level of Proteobacteria, followed by
Firmicutes, Bacteroidetes, and Actinobacteria. In the genus
subanalysis, excluding Hp which turns out to be the most
represented species, Streptococcus are commonly the second
detected bacteria [23, 24]. An interesting study by Ander-
sson et al., evaluating samples from both, Hp-positive and
healthy subjects, showed that the presence of Hp causes
a reduction of microbial diversity. Only 33 phylotypes were
found in Hp subjects compared to a rich and diversified
assortment of gastric microorganism of about 262 phylo-
types in healthy people, highlighting this difference [25].
In order to establish whether gastric microbiota alter-
ations found in concomitant withHp infection were induced
by hypochlorhydria, Parsons et al. analyzed gastric micro-
biota composition in various hypochlorhydric conditions
and in healthy subjects. As previously described, also in this
study the stomach of healthy subjects contains the widest
bacterial diversity compared with other groups. In-
terestingly, PPI group shows a microbiota characterization
which is similar in a healthy stomach, despite the hypo-
chlorhydric status due to the drug use. A significant dif-
ference in microbial diversity was found comparing healthy
subjects with Hp-related conditions and an interesting data
emerge from the comparison between Hp gastritis and Hp-
related atrophic gastritis. In fact, no significant differences
were found between these two conditions, suggesting that, in
the Hp subgroup patients, the role of bacteria may be su-
perior in inducing changes in the composition of gastric
microbiota compared with hypochlorhydria [24].
'e changes in gastric microbiota due to Hp infection
can be related to intrinsic properties of bacteria. In fact,Hp is
provided with oxidase, catalase, and urease activities. 'e
urease is a metalloenzyme able to convert urea into am-
monia and bicarbonate that is responsible for the local
increase in gastric pH and the safe passage into the gastric
lumen. Hp flagella enable the pathogen to pass through the
mucus layer driven by the pH gradient, thus permitting
gastric mucosal invasion. Once established, Hp exposes
adhesins (HopQ, HopP, and HopS) that permit a receptor-
specific close adhesion to gastric epithelial cells and con-
sequently the expression of CagA andVacA virulence factors
which mediate the cytotoxic activity [26–28]. Mucosal
damage attracts polymorphonuclear and other immune cells
that likely contribute to gastric damage by producing cy-
tokines and other proinflammatory substances [29]. Prob-
ably, these factors creating a hostile environment make
difficult the survival of the other bacteria, allowing the es-
tablishment of gastric dysbiosis.
2 Canadian Journal of Infectious Diseases and Medical Microbiology
3.Helicobacter pylori Eradication and
Probiotics Administration
According to the Maastricht V Consensus Report, the
standard triple therapy, proton pump inhibitor (PPI)
+ amoxicillin (AMX) + clarithromycin (CLR), is considered
the first-line empirical treatment in low CLR resistance
areas. When the regional resistance to CLR is high, con-
sidering 15% of population as the verge, nonbismuth qua-
druple therapy with PPI +AMC+metronidazole (MTZ)
+CLR is recommended. In all these cases, a bismuth qua-
druple therapy can be used as an alternative and it is rec-
ommended as first-line treatment in areas with high dual
CLR-MTZ resistance.'e benefit ofHp eradication has been
demonstrated in conditions like peptic ulcer disease, MALT
lymphoma, iron deficiency anemia, idiopathic thrombocy-
topenic purpura, and vitamin B12 deficiency [30]. Antibiotic
resistance is leading to increasing estimates of treatment
failures, as demonstrated by the raising rate of CLR-resistant
strains that has reached 40–50% in some areas of the world
[8].
Based on the literature data (Table 1), it emerges that
some probiotics associated with antibiotic therapy can
improve Hp eradication rate and moreover, can reduce
deleterious side effects due to antimicrobial therapy such as
nausea, vomiting, diarrhea, abdominal pain, bloating, and
taste disturbance that occasionally are responsible for the
withdrawal of the treatment [31, 32].
'e role of Lactobacillus strain administration in
the treatment of Hp infection and in preventing antimi-
crobial therapy side effects has been well documented.
'e supplementation of these probiotics can directly re-
duce Hp growth rate and Hp colonization. In a prospective,
randomized, controlled trial by Ojetti et al., adding
a probiotic (L. reuteri 1× 108 CFU tid for 14 days) to
levofloxacin-based second-line therapy showed an addi-
tional 20% eradication rate compared with antibiotic
treatment alone, followed by a consistent reduction of
symptoms such as diarrhea and nausea [33]. Armuzzi et al.
enrolled 120 asymptomatic Hp-positive subjects which
were randomly assigned to two treatment groups: one
receiving anti-Hp triple therapy (PPI 40mg bid, CLR
500mg bid, and tinidazole 500mg bid) and the other
receiving the same antibiotic therapy associated with
Lactobacillus GG-containing probiotic (6 ×109 of viable
bacteria) bid for 14 days. 'e analysis documented an
improvement in gastrointestinal symptoms in the probiotic
supplementation group with a significant reduction in taste
disturbances (p � 0.007), bloating (p � 0.01), and diarrhea
(p � 0.02). On the other hand, no significant differences in
eradication rates were reported (group 1 vs. group 2; PP:
80.7% vs. 80%, p � 0.9) [34]. Excellent results can be ob-
tained also by providing drinkable food supplements
containing Lactobacilli or its culture supernatant [35–38].
'e beneficial effects of Bifidobacterium administration
were analyzed by Chitapanarux et al. in a double-blind,
placebo-controlled trial using B. longum in addition to the
standard triple therapy. 'e results showed significant
beneficial effect on Hp eradication rate (PP: 28/30, 93.33%
vs. PP: 22/30, 73.33%, p � 0.04) and on diarrhea frequency
reduction (25% vs. 3.23%, p � 0.027) with no significant
outcomes on nausea (18.75 vs. 12.90%), taste disturbance
(15.63% vs. 12.90%), and epigastric pain (6.25 vs. 3.23%)
[39]. However, in a previous study by Yas¸ar et al. that in-
cluded 76 histopathologically proven Hp-positive patients,
the addition of Bifidobacterium DN-173-containing yogurt
to the standard triple therapy for 14 days resulted in the
eradication rate of 66% compared to 53% with antibiotic
therapy alone. Anyhow, the increase of Hp eradication rate
was not statistically significant [40].
Table 1: Efficacy of probiotics administration in addition to antimicrobial therapy compared to antimicrobial therapy alone in clinical trials
present in our review.
Study Patients Antimicrobialtherapy Probiotic Duration
Eradication
improvement
Side effect
reduction
Ojetti et al. [31] Adults
E: 20mg bid,
Lactobacillus reuteri (1× 108 CFU tid) 14 days Yes YesL: 500mg bid,
A: 1 g bid
Armuzzi et al. [33] Adults
P: 40mg bid,
Lactobacillus GG (6×109 CFU bid) 14 days No YesC: 500mg bid,
T: 500mg bid
Chitapanarux
et al. [34] Adults
E: 40mg bid,
Bifidobacterium longum (not specified) 4 weeks Yes YesC: 500mg bid,
A: 1 g bid
Yasar et al. [35] Adults
P: 40mg bid, Bifidobacterium DN-173 010-
1010CFU/g
yogurt 125ml
14 days No YesC: 500mg bid,
A: 1 g bid
Song et al. [36] Adults
O: 20mg bid,
Saccharomyces boulardii (3× l010 CFU/g) 4 weeks Yes YesC: 500mg bid,
A: 1 g bid
Du et al. [37] Adults
O: 20mg bid, Lactobacillus acidophilus (5 × 106),
Streptococcus faecalis (2.5 × 106), and
Bacillus subtilis (5 × 103) tid
2 weeks Yes NoC: 500mg bid,
A: 1 g bid
O: omeprazole; P: pantoprazole; E: esomeprazole; C: clarithromycin; A: amoxicillin; L: levofloxacin; T: tinidazole.
Canadian Journal of Infectious Diseases and Medical Microbiology 3
Saccharomyces boulardii, a yeast probiotic, was partic-
ularly effective in reducing side effects of the eradication
therapy. Song et al. reported that adding this probiotic to
CLR and AMX-based triple therapy for 4 weeks reached
85.4% eradication rate compared to 80% in the absence of
probiotic. Gastrointestinal side effects, in particular di-
arrhea, were more common in the latter group (p< 0.05)
[41]. A meta-analysis by Szajewska et al. including eleven
RCTs (2200 participants, among them 330 children) showed
that S. boulardii significantly increasedHp eradication rate but
below the aimed level. However, this probiotic significantly
reduced side effects, in particular diarrhea and nausea [42].
Based on the properties of probiotics, it is plausible that
a mixture of strains can improve Hp eradication rate. In
a trial of Du et al., a multistrain probiotic containing Lac-
tobacillus acidophilus, Streptococcus faecalis, and Bacillus
subtiliswas administered to the patients for two weeks before
antibiotic treatment or in another group for two weeks after
the eradication therapy. Both schedules were more effective
in eradicating Hp infection than the triple therapy alone
(81.6% and 82.4% vs. 61.5%), but there was no statistical
significance regarding the incidence of side effects [43]. A
meta-analysis by Wang et al. which included ten trials (1469
subjects) showed that probiotic addition using compounds
containing Lactobacillus and Bifidobacterium strains sig-
nificantly improves both Hp eradication rates and reduces
the incidence of antimicrobial therapy side effects. More-
over, the advantage of probiotics supplementation was
demonstrated independently of the type of eradication
therapy used in the trial, despite the bismuth-containing
therapy which could represent a potential failure due to the
inhibitory activity of bismuth against the probiotics [44].
Furthermore, a successive meta-analysis by Mcfarland et al.
confirmed that multistrain probiotics can be helpful as an
adjunct therapy for Hp eradication and in preventing
eradication side effects, but they concluded that not all
mixtures were equally effective [45]. Finally, Lau et al.
confirmed the utility of Lactobacillus, Bifidobacterium,
Saccharomyces, and probiotics mixtures in the treatment of
Hp infection in both adults and children, in Asian and non-
Asian population [46].
At present, the use of probiotics in children to treat Hp
infection is not clear. In the meta-analysis previously
mentioned by Wang et al., the children subgroup analysis
showed no probiotic efficacy on eradication rates and re-
duction of undesirable side effects [44]. Pacifico et al.
pointed out the controversial efficacy of probiotics use in
these patients. Seven trials comprising heterogeneous an-
tibiotic and probiotic therapies showed a general benefit in
eradication rates due to probiotic supplementation, but in
two only, the results were statistically significant, thus
concluding that no convincing evidence was present to
support the use of probiotics with triple therapy in children
[47]. Moreover, in 2015, the Latin American Expert group
consensus stated that at that time, there was a lack of suf-
ficient evidence to recommend the administration of pro-
biotics in this area [48]. However, other evidences suggest
that some probiotics like S. boulardii or L. casei alone or
multistrains (L. acidophilus+B. bifidum, B. mesentericus
+C. butyricum+ S. faecalis) can be helpful to treat Hp and
prevent side effects due to the eradication therapy in pe-
diatric patients, recommending their use [49–51].
'e beneficial effects of these probiotics against Hp
infection can be related to their intrinsic properties that can
depend on probiotic species (Figure 1). Lactobacilli have
been shown to possess the following properties:
(1) Production of antimicrobial substances, as bacte-
riocins that are synthesized by ribosomes and se-
creted by several bacteria including Lactobacilli.
'ese substances are provided with antimicrobial
activity and represent an important and successful
weapon against other microbial species like Hp
[13, 52]. Some bacteriocins, such as nisin, pediocin,
acidocin, and lacticin, contribute to homeostasis of
the complex GI tract ecosystem [53–55].
(2) Capacity to survive in the gastric acidic environment
by inducing lactic and volatile acids’ production
which has an inhibitory effect on Hp growth. 'e
effects of supplementation with L. salivarius have
been documented in a mouse model study, and its
efficacy has been related to the high amount of lactic
acid produced by the bacterium that interferes with
the urease activity of the pathogen [56]. Further-
more, in vitro, L. salivarius is able to reduce gastric
inflammation by modulating local cytokine secre-
tion, in particular of IL-8 directly related to neu-
trophil recruitment and mucosal inflammation,
probably as a response to the suppressed secretion of
CagA virulence factor [57].
(3) Ability to adhere at gastric and duodenal cells and
thus to perform a competitive action against path-
ogens. Mukai et al. found that two L. reuteri strains,
JCM 1081 and TM105, were able to bind specific
membrane glycolipids and therefore occupy the
potential site of Hp adhesion, inhibiting this path-
ogen gastric colonization [58].
Similar mechanisms of action were also described for
other probiotics. Bifidobacterium strains are able to produce
antimicrobial substances that can inhibit Hp growth, thus
improving eradication rates [10, 44, 59]. Interestingly,
a study in mice by Yu et al. suggested that a probiotic
mixture containing B. longum, L. acidophilus, and E. faecalis
can ameliorate Hp gastritis reducing the inflammatory re-
sponse by inhibiting cytokine secretion such as IL-8, TNF-α,
G-CSF, and GM-CSF [60]. Conversely, S. boulardii can
reduceHp adhesion at gastric and duodenal cells through its
neuraminidase activity able to selectively reduce the ex-
pression of α (2-3)-linked sialic acid on cell surface, a target
of Hp adhesions [61].
4. Conclusion
Our review highlights how some probiotic strains can im-
prove Hp eradication rates and prevent antimicrobial
therapy side effects, likely due to the capabilities of these
microorganisms to directly act against Hp, restoring
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a healthy microbiota. In Italy, the mean cost of probiotics in
addition to antimicrobial therapy based on the studies
present in this review is about 2 € per day of treatment per
patient. In our opinion, this cost is widely justified by the
reduction of side effects due to antibiotic therapy and the
increased eradication rate which reduces the need for
a second-line treatment. 'erefore, the administration of
probiotics may be considered an adjunctive treatment es-
pecially when Hp eradication fails. However, not all pro-
biotics are alike useful, and probably, the curative effects are
strain dependent. Additional studies are necessary to better
understand their role in Hp infection, particularly when
using the updated eradication schedules.
At present, few studies or meta-analysis are available on
a direct comparison between beneficial effects of different
probiotics species during antimicrobial therapy. However,
according to the available data and to the Maastricht V
Consensus Report statement “Certain probiotics may have
a beneficial effect on Hp eradication” [30], we recommend
the use of Lactobacillus, Bifidobacterium, and Saccharomyces
strains. Nevertheless, in our opinion, more trials with
probiotics should be tailored to the state of gastric micro-
biota composition before and after Hp eradication therapy,
inasmuch as it could explain the role of various bacteria in
the development of gastric diseases.
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